Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - Introduction: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Migrate to Template:ReferenceData for PageForms (GxPlexBot) |
||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 | ||
| | |module=4 | ||
| | |unit=4.1.1 | ||
| | |scope=HM | ||
| | |doc_part=4.4 - Introduction | ||
| | |language=EN | ||
|entry_by=Florian Adragna | |||
|contributors= | |||
|tags=TAG-00328-Com-egu ++ TAG-00203-Cli-lin ++ TAG-00246-Inv-hte ++ TAG-00111-Agr-chr | |||
|tags_display=[[Glossary:TAG-00328-Com-egu|Compliance]], [[Glossary:TAG-00203-Cli-lin|Investigation plan]], [[Glossary:TAG-00246-Inv-hte|Investigator responsibilities]], [[Glossary:TAG-00111-Agr-chr|Written agreement]] | |||
|comment=Investigator obligation to comply with the CIP | |||
|content=4.4 Compliance with the protocol | |||
| | |||
| | |||
4.4 Compliance with the protocol | |||
The investigator must agree and sign the protocol ( or another legally acceptable document mentioning the agreement with the protocol) with the sponsor, and confirm in writing that he or she has read, understands and will work according to the protocol and Good Clinical Practice. | The investigator must agree and sign the protocol ( or another legally acceptable document mentioning the agreement with the protocol) with the sponsor, and confirm in writing that he or she has read, understands and will work according to the protocol and Good Clinical Practice. | ||
| Line 50: | Line 20: | ||
The investigator may take any steps judged necessary to protect the safety of the trial subject, whether specified in the protocol or not. Any such steps must be documented. | The investigator may take any steps judged necessary to protect the safety of the trial subject, whether specified in the protocol or not. Any such steps must be documented. | ||
}} | |||
Revision as of 12:55, 16 July 2026
| Document information | |
|---|---|
| Reference | WHO WHO - Guidelines for GCP for trials on
pharmaceutical products* 1995 |
| Validity area | WHO |
| Scope(s) | HM |
| Document name | WHO - Guidelines for GCP for trials on
pharmaceutical products* |
| Version / Revision | 1995 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | World Health Organization
WHO Technical Report Series, No. 850, 1995, Annex 3 Guidelines for good clinical practice (GCP) for trials on pharmaceutical products* |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 — Unit 4.1.1 |
| Scope | HM |
| Document part | 4.4 - Introduction |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Compliance, Investigation plan, Investigator responsibilities, Written agreement |
Content
4.4 Compliance with the protocol The investigator must agree and sign the protocol ( or another legally acceptable document mentioning the agreement with the protocol) with the sponsor, and confirm in writing that he or she has read, understands and will work according to the protocol and Good Clinical Practice.
The investigator is responsible for ensuring that the protocol is strictly followed. The investigator should not make any changes in the study without the agreement of the sponsor, except when necessary to eliminate an apparent immediate hazard or danger to a trial subject. Any change should be in the form of a protocol amendment, appended to the original protocol and signed by the investigator and the sponsor. Amendments which are likely to affect the safety of a subject or the conduct of the clinical trial should be submitted in writing to the ethics committee (see Section 3.2) and drug regulatory authority and implemented only after approval has been received.
The investigator may take any steps judged necessary to protect the safety of the trial subject, whether specified in the protocol or not. Any such steps must be documented.
